(Q59692140)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

0 references

1 reference

pneumococcal conjugate vaccine

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

7

Milton C Weinstein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

Lisa J McGarry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

4

Keith P Klugman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

6

Kristen E Gilmore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Jaime L Rubin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

David R Strutton

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

28 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

7634-7643

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Economic burden of pneumonia in an employed population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Complications of meningococcal disease in college students.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

An economic analysis of the universal varicella vaccination program in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Health benefits, risks, and cost-effectiveness of influenza vaccination of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Parapneumonic empyema deaths during past century, Utah.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.049

10.1016/J.VACCINE.2010.09.049

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883739%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference